ArticleAntimicrobial resistance and infection control2019
Phenotypic and genotypic characterization of carbapenem-resistant
Article in Antimicrobial resistance and infection control, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 91 citations in OpenAlex.
- Multiplex RPA-CRISPR/Cas12a Assay for Rapid Detection of Class D OXA-Type Carbapenem-ResistantBiosensors · 2026Article
- Phenotypic and molecular characterization of carbapenem resistance among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii.BMC microbiology · 2026Article
- Carbapenem-ResistantMicroorganisms · 2026Article
- Phenotype-Genotype Discordance in Antimicrobial Resistance ofPathogens (Basel, Switzerland) · 2026Review
- Whole genome analysis of carbapenem resistantNew microbes and new infections · 2026Article
- Genomic insights into ST85 and ST158 belonging to recently emerged global clones of multidrug-resistant Acinetobacter baumannii isolates from Egypt: in vitro assessment of repurposed drug-antibiotic combinations.Annals of clinical microbiology and antimicrobials · 2025Article
- In vitro activity of meropenem-vaborbactam combinations and eravacycline against carbapenem-resistant Acinetobacter baumannii.Scientific reports · 2025Article
- Minneola tangelo essential oil exhibits antibacterial activity against multidrug-resistant pathogens while maintaining cell safety.BMC complementary medicine and therapies · 2025Article
- Comparative genomics of Acinetobacter baumannii from Egyptian healthcare settings reveals high-risk clones and resistance gene mobilization.BMC infectious diseases · 2025Article
- Emergence of NDM-1- and OXA-23-Co-ProducingMicroorganisms · 2025Article
- β-Lactamase diversity inAntimicrobial agents and chemotherapy · 2025Article
- Antimicrobial Resistance Patterns and Epidemiological Distribution of Pathogenic Bacteria in the Pediatric Intensive Care Unit at Beijing Children's Hospital: A Decade-Long Retrospective Analysis (2014-2023).Infection and drug resistance · 2025Article
- Article
- Co-production of metallo-β-lactamase and OXA-type β-lactamases in carbapenem-resistant Acinetobacter baumannii clinical isolates in North East India.World journal of microbiology & biotechnology · 2024Article
- [Characteristics of drug resistance and biofilm formation in carbapenem-resistantZhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2024Article
- Examining the role of Acinetobacter baumannii plasmid types in disseminating antimicrobial resistance.npj antimicrobials and resistance · 2024Article
- Molecular characterization of carbapenem-resistance in Gram-negative isolates obtained from clinical samples at Jimma Medical Center, Ethiopia.Frontiers in microbiology · 2024Article
- Article
- Associations betweenMedicina (Kaunas, Lithuania) · 2023Article
- Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Antibiotic use is largely under-regulated in Egypt leading to the emergence of resistant isolates. Carbapenems are last resort agents to treat Methods: Carbapenemase production was assessed by a number of phenotypic methods: modified Hodge test (MHT), carbapenem inactivation method (CIM), combined disc test (CDT), CarbAcineto NP test and boronic acid disc test. Polymerase chain reaction (PCR) was used to screen the isolates for the presence of some genes responsible for resistance to carbapenems, as well as some insertion sequences. Results: PCR amplification of class D carbapenemases revealed the prevalence of Conclusions: The widespread detection of carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.